Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the day at $4.62. Traded volume was 1.16million shares in the last session and the average volume of the stock remained 1.07million shares. The beta of the stock remained 2.40. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) insider ownership is 1.80%.

Idenix Pharmaceuticals Inc (NASDAQ:IDIX) announced that the Company has filed patent infringement lawsuits against Gilead Sciences, Inc. (Gilead) and/or certain of its subsidiaries in France, Germany, and the United Kingdom. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) informed that the lawsuits allege that Gilead infringes the Company’s recently-granted, co-owned European patent EP 1 523 489 that covers 2′-methyl-2′-fluoro nucleosides for treating the hepatitis C virus. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) dropped -3.38 percent to $6.01 Wednesday on volume of 989.701.00million shares. The intra-day range of the stock was $5.82 to $6.34. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has a market capitalization of $906.33million.

Synthetic Biologics Inc (NYSEMKT:SYN) has been working on the clinical data of its specialty product for some time. With the results of the trials pending announcement, investor sentiment and trader sentiment appear to be bullish. Synthetic Biologics Inc (NYSEMKT:SYN) has reported that the Phase II trials for Multiple Sclerosis is already underway and the company is likely to see high traction based on the results. Synthetic Biologics Inc (NYSEMKT:SYN)’s stock on Apr 02, 2014 reported a decrease of -1.95% to the closing price of $2.51. Its fifty two weeks range is $0.95 -$3.64. The total market capitalization recorded $145.58million. The overall volume in the last trading session was 1.16million shares. In its share capital, SYN has 57.98million outstanding shares.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), which just appointed a new senior vice president and chief business officer — is 4.7% lower at $8.12. Nevertheless, intraday call volume is running at a 22% mark-up to its average, with more than 6,400 contracts exchanged. For comparison, fewer than 600 ARIA puts have traded thus far. On Wednesday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -5.40% to close the day at $8.06. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -7.89%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is 18.18%.